



June 8, 2026

TO: Opioid Abatement Fund Council Members

FROM: Katy Fallon Brown, Director of Texas Opioid Abatement Fund Council

RE: **Summary of Receipts and Expenditures of the Opioid Abatement Fund Council**

This memorandum reflects funds received and available from settlement agreements or court orders as of June 8, 2026, totaling \$568,259,677.10. This amount includes \$275,000,000 that the Council has allocated to three annual Grant Issuance Plans and does account for \$2,963,274.72 reimbursed to grantees. It does not include the \$146,232,653.02 allocated to the state legislature.*

Trust Fund Activity	
Description	Amount
Receipts	
Settlement Receipts	\$715,622,383.83
Interest	\$64,953,850.97
Total Revenues	\$780,576,234.80
Expenditures	
Texas Access for Justice	(\$5,000,000.00)
Political Subdivision Disbursements	(\$112,525,716.53)
Hospital District Disbursements	(\$91,827,566.45)
Reimbursements to Grantees	(\$2,963,274.72)
Total Expenses	(\$212,316,557.70)
Ending Trust Fund Balance – June 8, 2026	\$568,259,677.10

Grant Allocations, Awards, and Reimbursements Paid to Date			
Grant	Allocation	Award Amount (Date)	Expenditures
2024 Naloxone Distribution	\$25 Million	\$25 Million (Aug 2024)	\$1,273,912.83
2024 K-12 Opioid Prevention Education	\$25 Million	\$25 Million (Jan 2025)	\$116,846.23
2024 Peer-To-Peer Workforce Enhancement	\$25 Million	\$10 Million (Apr 2025)	\$701,516.12
2025 Short-term Community-based Opioid Recovery Effort (CORE)	\$25 Million	\$20.69 Million (Sept 2025)	\$870,999.54
2025 Recovery Housing	\$25 Million	\$25 Million (Dec 2025)	
2025 Long-term CORE	\$50 Million		
2026 Criminal Justice	\$25 Million		
2026 CORE Regional	\$75 Million		
Grand Total	\$275 Million	\$105.69 Million	\$2,963,274.72

Trust Fund Share		
Date	Description	Amount
June 2022	Endo	\$38,575,907.50
June 2022	Teva	\$22,075,375.00
FY 2022	Interest	\$108,831.01
October 2022	J&J/Jansen	\$164,004,732.50
November 2022	Texas Access to Justice Foundation	(\$5,000,000.00)
January 2023	Global	\$25,325,280.96
June 2023	Mallinckrodt	\$6,740,034.03
August 2023	Teva	\$3,500,000.00
FY 2023	Interest	\$8,013,996.10
September 2023	McKinsey	\$22,819,947.11
October 2023	CPA Administrative Allocation	(\$493,000.00)
November 2023	Global	\$21,222,124.39
November 2023	Mallinckrodt	\$7,929,451.81
February 2024	Walmart	\$41,982,381.67
April 2024	Global	\$19,686,697.44
April 2024	Publicis	\$14,585,010.94
August 2024	CPA Administrative Allocation	\$493,000.00
August 2024	Global	\$30,198,894.76
August 2024	Hospital District Allocation	(\$65,770,854.13)
FY 2024	Interest	\$16,703,695.77
September 2024	Walmart	\$44,896,111.26
September 2024	CVS	\$7,849,308.62
September 2024	Walgreens	\$19,866,315.75
October 2024	Allergan	\$16,861,880.87
February 2025	Walmart	\$1,833,844.96
February 2025	Naloxone Grant Reimbursement	(\$26,368.10)
April 2025	Walgreens	\$2,361,423.03
May 2025	Hospital District Allocation	(\$14,263,973.29)
June 2025	Naloxone Grant Reimbursement	(\$31,556.07)
June 2025	K12 Grant Reimbursement	(\$64,934.21)
June 2025	Kroger	\$3,201,065.71
July 2025	Naloxone Grant Reimbursement	(\$59,725.59)
August 2025	Allergan	\$12,972,725.40
August 2025	CVS	\$7,898,016.76
August 2025	Global	\$44,661,310.73
August 2025	Naloxone Grant Reimbursement	(\$62,576.15)
August 2025	CVS	\$1,111,209.01
FY 2025	Interest	\$20,717,269.83
September 2025	Naloxone Grant Reimbursement	(\$366,473.82)
October 2025	Naloxone Grant Reimbursement	(\$231,291.20)
October 2025	Walmart	\$4,430,537.30
November 2025	K12 Grant Reimbursement	(\$20,035.80)

Trust Fund Share		
Date	Description	Amount
November 2025	P2P Grant Reimbursement	(\$47,504.49)
December 2025	Naloxone Grant Reimbursement	(\$160,385.47)
December 2025	P2P Grant Reimbursement	(\$30,915.25)
January 2026	P2P Grant Reimbursement	(\$100,721.51)
January 2026	ST CORE Grant Reimbursements	(\$11,708.10)
February 2026	ST CORE Grant Reimbursements	(\$81,826.08)
February 2026	P2P Grant Reimbursement	(\$80,449.11)
March 2026	ST CORE Grant Reimbursements	(\$71,548.94)
March 2026	P2P Grant Reimbursement	(\$104,283.18)
March 2026	Hospital District Allocation	(\$11,792,739.03)
April 2026	ST CORE Grant Reimbursements	(\$270,500.52)
April 2026	P2P Grant Reimbursement	(\$68,021.07)
April 2026	Naloxone Grant Reimbursement	(\$335,536.43)
April 2026	Walgreens	\$2,361,423.03
May 2026	ST CORE Grant Reimbursements	(\$263,540.25)
May 2026	K12 Grant Reimbursement	(\$31,876.22)
May 2026	P2P Grant Reimbursement	(\$75,913.43)
May 2026	Kroger	\$1,800,778.11
May 2026	Teva	\$10,500,000.00
June 2026	Walgreens	\$1,225,000.00
June 2026	ST CORE Grant Reimbursements	(\$171,875.65)
June 2026	P2P Grant Reimbursement	(\$193,708.08)
FY 2026 to date	Interest	\$16,575,336.01
		\$564,805,076.20

Subdivision Share		
Date	Description	Amount
June 2022	Endo	\$7,873,408.75
June 2022	Teva	\$4,730,437.50
FY 2022	Interest	\$7,069.86
October 2022	J&J/Jansen	\$30,166,610.48
January 2023	Global	\$3,940,050.62
August 2023	Teva	\$750,000.00
March 2023	Distribution	(\$47,088,165.36)
June 2023	Mallinckrodt	\$1,444,293.01
FY 2023	Interest	\$677,775.48
September 2023	McKinsey	\$4,027,049.49
November 2023	Global	\$3,938,138.54
November 2023	Mallinckrodt	\$1,699,168.24
February 2024	Walmart	\$8,996,224.64
April 2024	Global	\$4,218,578.02

Subdivision Share		
Date	Description	Amount
April 2024	Publicis	\$3,125,359.49
April 2024	Distribution	(\$9,160,657.93)
August 2024	Global	\$4,207,105.37
FY 2024	Interest	\$679,608.61
September 2024	Walmart	\$9,620,595.28
September 2024	CVS	\$1,681,994.71
September 2024	Walgreens	\$4,257,067.66
October 2024	Allergan	\$3,613,260.18
February 2025	Walmart	\$392,966.77
March 2025	Distribution	(\$44,690,490.84)
April 2025	Walgreens	\$506,019.22
June 2025	Kroger	\$685,942.65
August 2025	Allergan	\$2,779,869.73
August 2025	CVS	\$1,692,432.16
August 2025	Global	\$4,207,105.37
August 2025	CVS	\$238,116.21
FY 2025	Interest	\$1,203,262.42
October 2025	Walmart	\$949,400.85
March 2026	Distribution	(\$11,586,402.40)
April 2026	Walgreens	\$506,019.22
May 2026	Teva	\$2,250,000.00
May 2026	Kroger	\$385,881.02
June 2026	Walgreens	\$262,500.00
FY 2026 to date	Interest	\$267,005.88
		\$3,454,600.90

Unappropriated General Revenue		
Date	Description	Amount
April 2021	McKinsey	\$1,397,982.70
		\$1,397,982.70

*In addition to the funds deposited into the Texas Opioid Abatement Trust Fund, certain opioid settlement proceeds were allocated to the State of Texas pursuant to the applicable settlement agreement. Since fiscal year 2023, the Legislature has appropriated approximately \$56.9 million from General Revenue-Dedicated Account No. 5189 to support programs at the Health and Human Services Commission, the University of Texas Health Science Center at San Antonio, the Texas Education Agency, and the Texas Department of Emergency Management, as well as the administration of the O AFC program.